Fallone C A, Barkun A N, Göttke M U, Beech R N
Division of Gastroenterology, Royal Victoria Hospital, McGill University, Montreal, QC, Canada.
Can J Microbiol. 1998 Mar;44(3):201-10.
Helicobacter pylori is present in 40-60% of the population and approximately 10-20% of these infected individuals suffer from a H. pylori associated disease such as peptic ulcer disease or gastric cancer. This article reviews the potential bacterial determinants responsible for and markers predictive of both the acquisition of H. pylori infection and subsequent clinical outcome; i.e., asymptomatic infection or disease. The acquisition of H. pylori infection depends on exposure (hence the increased risk in lower socioeconomic groups and developing nations) to viable bacteria with at least a functional urease gene in a susceptible host. Once infection occurs, bacterial virulence factors, including the vacuolating cytotoxin, and genes of the cag pathogenicity island, as well as nonbacterial factors may determine disease outcome. Future research is being directed at discovering other bacterial virulence factors responsible for the different clinical outcomes of H. pylori infection. This will be greatly enhanced by the recent release of the complete genome sequence of H. pylori. The determination of the relative importance of each of these recognized and other as yet unrecognized factors responsible for disease outcome will assist in the appropriate targeting of patients in the treatment of H. pylori infection.
幽门螺杆菌存在于40%-60%的人群中,这些受感染个体中约有10%-20%患有与幽门螺杆菌相关的疾病,如消化性溃疡病或胃癌。本文综述了与幽门螺杆菌感染的获得及后续临床结局(即无症状感染或疾病)相关的潜在细菌决定因素和预测标志物。幽门螺杆菌感染的获得取决于在易感宿主中接触(因此社会经济地位较低群体和发展中国家风险增加)具有至少一个功能性脲酶基因的活细菌。一旦发生感染,包括空泡毒素、cag致病岛基因在内的细菌毒力因子以及非细菌因素可能决定疾病结局。未来的研究方向是发现导致幽门螺杆菌感染不同临床结局的其他细菌毒力因子。幽门螺杆菌全基因组序列的近期发布将极大地推动这一研究。确定这些已确认和其他尚未确认的导致疾病结局的因素各自的相对重要性,将有助于在幽门螺杆菌感染治疗中对患者进行恰当的靶向治疗。